1. Home
  2. PACB vs DBVT Comparison

PACB vs DBVT Comparison

Compare PACB & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PACB
  • DBVT
  • Stock Information
  • Founded
  • PACB 2000
  • DBVT 2002
  • Country
  • PACB United States
  • DBVT France
  • Employees
  • PACB N/A
  • DBVT N/A
  • Industry
  • PACB Biotechnology: Laboratory Analytical Instruments
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PACB Industrials
  • DBVT Health Care
  • Exchange
  • PACB Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • PACB 369.5M
  • DBVT 434.7M
  • IPO Year
  • PACB 2010
  • DBVT N/A
  • Fundamental
  • Price
  • PACB $1.41
  • DBVT $14.97
  • Analyst Decision
  • PACB Buy
  • DBVT Buy
  • Analyst Count
  • PACB 7
  • DBVT 4
  • Target Price
  • PACB $1.90
  • DBVT $14.81
  • AVG Volume (30 Days)
  • PACB 6.8M
  • DBVT 110.9K
  • Earning Date
  • PACB 11-06-2025
  • DBVT 11-05-2025
  • Dividend Yield
  • PACB N/A
  • DBVT N/A
  • EPS Growth
  • PACB N/A
  • DBVT N/A
  • EPS
  • PACB N/A
  • DBVT N/A
  • Revenue
  • PACB $156,110,000.00
  • DBVT $3,800,000.00
  • Revenue This Year
  • PACB $6.17
  • DBVT $1,743.46
  • Revenue Next Year
  • PACB $15.63
  • DBVT $1,044.34
  • P/E Ratio
  • PACB N/A
  • DBVT N/A
  • Revenue Growth
  • PACB N/A
  • DBVT N/A
  • 52 Week Low
  • PACB $0.85
  • DBVT $2.21
  • 52 Week High
  • PACB $2.72
  • DBVT $16.98
  • Technical
  • Relative Strength Index (RSI)
  • PACB 51.90
  • DBVT 75.66
  • Support Level
  • PACB $1.39
  • DBVT $9.19
  • Resistance Level
  • PACB $1.60
  • DBVT $16.98
  • Average True Range (ATR)
  • PACB 0.10
  • DBVT 1.02
  • MACD
  • PACB 0.02
  • DBVT 0.62
  • Stochastic Oscillator
  • PACB 48.15
  • DBVT 75.26

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: